The company has embraced an innovation-driven strategy, and it has continuously enhanced its R&D capabilities in recent years. It has built multiple core technology platforms covering cutting-edge fields such as RNAi therapeutics, radionuclide drug conjugates (RDC), FIC & BIC antibodies, recombinant drugs, and innovative small-molecule drugs etc.
Proportion of average R&D investment
On-going research projects (incl. both innovative and high-value projects)
Professionals in R&D and Clinical Medicine
Proportion of R&D team with master and PhD
Four R&D Directions
Characteristic API
High-end generic drugs
Innovative drugs
Novel drug delivery system
Focused Disease Areas
Oncology
Immunology & Inflammation
Cardiovascular & Metabolic Diseases
Respiratory & Anti-infective
Neurology & Psychiatry
Rare diseases and others
Key R&D Institutions
Pharmaceutical Research Institute
Purity Research Institute
ScinnoHub Pharmaceuticals
Shanghai Hongcheng Biopharma
Brilliant Harpoon Biotechnology
Haihe Pharmaceuticals
Suvanta Pharma
R&D Innovation Features
Differentiated Pipelines
International R&D Team
Scientific and Precise Project Initiations
Diversified Cooperation Models
Technology Platforms
R&D Institutions
R&D Talents
The company values the introduction and cultivation of innovative talent, has a well-established talent incentive mechanism, and integrates talent development with its strategic direction in science and technology to enable them to fully exercise their innovative abilities and meet the needs of the company, the industry, and society
Intellectual Property
Patent Applications
Domestic Authorized Patents
Overseas Patent Applications
Overseas Authorized Patents